Sweden-based Metabogen, a metagenomics research spinout of Gothenburg University, secured the remaining SKr4m ($400,000) of a SKr12m investment from healthcare company BioGaia on Wednesday.
Metagenomics is the study of genetic material found in an environmental sample.
BioGaia announced the SKr12m deal in 2014 and said it would release the funds over two years subject to MetaboGen meeting undisclosed targets, starting with an initial injection of SKr4m.
The second SKr4m tranche was released in December 2015, and as Metabogen has since…
